Journal of Personalized Medicine (Dec 2021)

Genome-Wide Association Study of Lithium-Induced Dry Mouth in Bipolar I Disorder

  • Lawrence Shih-Hsin Wu,
  • Ming-Chyi Huang,
  • Chih-Ken Chen,
  • Chen-Yang Shen,
  • Cathy Shen-Jang Fann,
  • Chun-Yuan Lin,
  • Chih-Chien Lin,
  • Andrew Tai-Ann Cheng

DOI
https://doi.org/10.3390/jpm11121265
Journal volume & issue
Vol. 11, no. 12
p. 1265

Abstract

Read online

Dry mouth is a rather common unpleasant adverse drug reaction (ADR) to lithium treatment in bipolar disorders that often lead to poor adherence or early dropout. The aim of this study was to identify the genetic variants of dry mouth associated with lithium treatment in patients with bipolar I (BPI) disorder. In total, 1242 BPI patients who had ever received lithium treatment were identified by the Taiwan Bipolar Consortium for this study. The proportions of patients who experienced impaired drug compliance during lithium medication were comparable between those only with dry mouth and those with any other ADR (86% and 93%, respectively). Dry mouth appeared to be the most prevalent (47.3%) ADR induced by lithium treatment. From the study patients, 921 were included in a genome-wide association study (GWAS), and replication was conducted in the remaining 321 patients. The SNP rs10135918, located in the immunoglobulin heavy chain locus (IGH), showed the strongest associations in the GWAS (p = 2.12 × 10−37) and replication groups (p = 6.36 × 10−13) (dominant model) for dry mouth with a sensitivity of 84.9% in predicting dry mouth induced by lithium. Our results may be translated into clinical recommendation to help identify at-risk individuals for early identification and management of dry mouth, which will improve medication adherence.

Keywords